Fonseca-Gomes, JoãoLoureiro, Joana ATanqueiro, SaraMouro, FranciscoRuivo, PedroCarvalho, TâniaSebastião, Ana MDiógenes, Maria JoséPereira, Maria Carmo2021-04-072021-04-072020Int J Nanomedicine. 2020 Nov 5;15:8609-86211176-9114http://hdl.handle.net/10451/47280© 2020 Fonseca-Gomes et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Nanoparticles (NPs), as drug delivery systems, appear to be a promising tool for prolonged therapeutic strategies as they allow a controlled drug release over time. However, most of the studies found in the literature simply contemplate the use of a single or low number of dosages with low NPs concentrations. In the context of chronic diseases, like Alzheimer's disease, cancer or human immunodeficiency virus (HIV), where the therapeutic scheme is also chronic, studies with numerous repeated dosages are often neglected.engPLGA nanoparticlesDrug delivery systemsLiposomesLong-lasting treatmentNanocarriersSolid lipid nanoparticlesjournal article10.2147/IJN.S2670071178-2013